ArticlebioRxiv : the preprint server for biology2025
Validation of diverse and previously untraceable Sendai virus copyback viral genomes by Direct RNA Sequencing.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Copyback viral genomes (cbVGs) are truncated viral genomes with complementary ends produced when the viral negative-sense RNA virus polymerase detaches from the replication template and resumes elongation from the nascent strand. Despite advances in methods to identify cbVGs based on the site of polymerase break and rejoin, PCR-based tools cannot provide full length sequences of most cbVGs and/or can introduce errors and artifacts during cbVG amplification. These limitations have painted a limited picture of the diverse population of cbVGs generated during infection. To improve our ability to obtain native full-length sequences of cbVGs, we optimized Direct RNA Sequencing (DRS) as a fast and simple tool to sequence full-length cbVGs and designed a BLAST-based analysis approach to identify cbVGs from long-read sequencing data. We analyzed the DRS outputs of multiple Sendai virus stocks to highlight both the utility and limitations of this tool. We found that to capture the dominant 546 nucleotide cbVG produced by Sendai virus strain Cantell, the length of complementarity between the virus trailer and the DRS oligonucleotide should optimally be increased to up to 32 nucleotides. We also demonstrate comparable quality of cbVG sequences by DRS from as little RNA as 17.6ng from the media fraction or 50ng of from the cellular fraction of cells infected with SeV, in contrast to the recommended 1000ng. Importantly, we validated different cbVG species from two recombinant Sendai virus stocks, including for the first time cbVGs whose break positions occurred at or near position one in the reference genome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.